MannKind Corporation develops and commercializes inhaled therapeutic products for endocrine and orphan lung diseases. Products include Afrezza, V-Go, Tyvaso DPI, MNKD-101, and MNKD-201. The company has agreements with United Therapeutics, Vertice Pharma, Thirona, Biomm S.A., and Cipla Ltd. MannKind is headquartered in Danbury, Connecticut, and was incorporated in 1991.
| Indicator | Value |
|---|---|
| PER | 43.8 |
| EV/EBITDA | 14.2 |
| Price/Free Cash Flow' | 36.8 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 0.8 |